Qiagen (NYSE:QGEN) Receives Average Rating of "Hold" from Brokerages

Qiagen (NYSE:QGEN - Get Free Report) has been given a consensus recommendation of "Hold" by the ten analysts that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $48.42.

A number of research firms have weighed in on QGEN. Baird R W lowered shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Robert W. Baird boosted their target price on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th. Finally, Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $45.48 on Friday. The firm's 50 day moving average is $42.26 and its two-hundred day moving average is $42.05. Qiagen has a 52 week low of $37.63 and a 52 week high of $49.30. The firm has a market capitalization of $10.11 billion, a P/E ratio of 126.64, a PEG ratio of 2.39 and a beta of 0.67. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.05. The firm had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The firm's quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.44 earnings per share. Analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SVB Wealth LLC purchased a new stake in Qiagen in the first quarter valued at approximately $31,000. Brown Brothers Harriman & Co. purchased a new stake in Qiagen in the fourth quarter valued at approximately $37,000. EverSource Wealth Advisors LLC raised its stake in Qiagen by 152.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock valued at $39,000 after purchasing an additional 526 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in Qiagen by 148.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after purchasing an additional 835 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in Qiagen in the first quarter valued at approximately $94,000. Institutional investors own 70.00% of the company's stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.